U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...
The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...
The primary endpoint is progression-free survival (PFS) in participants treated with the combination of zolbetuximab plus mFOLFOX6 compared to those treated with placebo plus mFOLFOX6. Secondary ...
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved zolbetuximab (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback